...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Clinical Ultrasound: JCU >Percutaneous radiofrequency ablation of malignant liver tumors with ultrasound and CT fusion imaging guidance
【24h】

Percutaneous radiofrequency ablation of malignant liver tumors with ultrasound and CT fusion imaging guidance

机译：超声和CT融合成像指导对恶性肝肿瘤进行经皮射频消融

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: To evaluate the feasibility, accuracy, and utility of sonography (US) and CT fusion imaging guidance for radiofrequency ablation (RFA) of malignant liver tumors not visualized on conventional US. Methods: Seventy-seven patients with hepatocellular carcinoma and 15 patients with metastatic liver cancer with a total of 136 lesions underwent RFA with US and CT fusion imaging guidance. The mean number of punctures, success rate of a single ablation session, local tumor progression rates, and long-term outcome were evaluated. Treatment efficacy was evaluated by dynamic CT and contrast-enhanced US 1 month after RFA. Results: RFA was technically feasible in all patients, and no major complications occurred. The mean±SD time needed to synchronize US and CT images was 13.9±11.9 minutes (range, 5-55 minutes). The success rate of a single ablation session was 83.8% (114/136), and tumor residue was present in 7.4% of lesions (10/136). The mean number of treatment sessions was 1.2±0.5 sessions. During follow-up, local tumor progression was observed for 15 (11.9%) lesions. Distant tumor recurrence was found in 51 (55.4%) patients. Conclusions: US and CT fusion-assisted RFA is a safe and efficacious treatment for patients with hepatocellular carcinoma and metastatic liver cancer.
机译：背景：评价超声检查（US）和CT融合成像指导在常规US上未发现的恶性肝肿瘤射频消融（RFA）的可行性，准确性和实用性。方法：77例肝细胞癌患者和15例转移性肝癌患者（共136个病变）在US和CT融合成像指导下进行了RFA。评估平均穿刺次数，单次消融成功率，局部肿瘤进展率和长期预后。 RFA治疗后1个月，通过动态CT和增强造影剂评估治疗效果。结果：RFA在所有患者中在技术上都是可行的，并且没有发生重大并发症。同步US和CT图像所需的平均±SD时间为13.9±11.9分钟（范围5-55分钟）。一次消融治疗的成功率为83.8％（114/136），并且在7.4％的病变中有肿瘤残留（10/136）。平均疗程为1.2±0.5次。在随访过程中，观察到15例（11.9％）病变的局部肿瘤进展。在51（55.4％）位患者中发现远处的肿瘤复发。结论：US和CT融合辅助RFA对肝细胞癌和转移性肝癌患者是一种安全有效的治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号